MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles

Nature Reviews Drug Discovery

Volumn 11, Issue 11, 2012, Pages 860-872

  Van Rooij, Eva ^a   Olson, Eric N ^b  

^a MiRagen Therapeutics   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CARDIOVASCULAR AGENT; MICRORNA 133 INHIBITOR; MICRORNA 145 INHIBITOR; MICRORNA 15 INHIBITOR; MICRORNA 155 INHIBITOR; MICRORNA 199B INHIBITOR; MICRORNA 208A INHIBITOR; MICRORNA 21 INHIBITOR; MICRORNA 23 INHIBITOR; MICRORNA 24 INHIBITOR; MICRORNA 27 INHIBITOR; MICRORNA 29 INHIBITOR; MICRORNA 320 INHIBITOR; MICRORNA 33 INHIBITOR; MICRORNA 92A INHIBITOR; MICRORNA INHIBITOR; MIRAVIRSEN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INDICATION; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; GAIN OF FUNCTION MUTATION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEPATITIS C; HUMAN; LEG ISCHEMIA; LOSS OF FUNCTION MUTATION; NONHUMAN; OBESITY; ORGAN DISTRIBUTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RNA SYNTHESIS; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; VIRUS MYOCARDITIS;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS;

EID: 84868475728     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3864     Document Type: Review

References (107)

1. van Rooij, E. et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl Acad. Sci. USA 103, 18255-18260 (2006). (Pubitemid 44871645)
2. Ikeda, S. et al. Altered microRNA expression in human heart disease. Physiol. Genomics 31, 367-373 (2007). (Pubitemid 350127777)
3. Thum, T. et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267 (2007). (Pubitemid 47196561)
4. Bonauer, A., Boon, R. A. & Dimmeler, S. Vascular microRNAs. Curr. Drug Targets 11, 943-949 (2010).
5. Zampetaki, A. & Mayr, M. MicroRNAs in vascular and metabolic disease. Circ. Res. 110, 508-522 (2012).
6. Bonauer, A. et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324, 1710-1713 (2009).
7. Boon, R. A. et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ. Res. 109, 1115-1119 (2011).
8. Caruso, P. et al. A role for miR-145 in pulmonary arterial hypertension. Circ. Res. 111, 290-300 (2012).
9. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 (2008).
10. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105, 13027-13032 (2008).
11. Wang, S. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15, 261-271 (2008).
12. Xin, M. et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 23, 2166-2178 (2009).
13. Hullinger, T. G. et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110, 71-81 (2012).
14. Mutharasan, R. K., Nagpal, V., Ichikawa, Y. & Ardehali, H. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt-and p53-dependent pathways and exerts cytoprotective effects. Am. J. Physiol. Heart Circ. Physiol. 301, H1519-H1530 (2011).
15. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
16. Orom, U. A., Nielsen, F. C. & Lund, A. H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 30, 460-471 (2008). (Pubitemid 351672378)
17. Tay, Y., Zhang, J., Thomson, A. M., Lim, B. & Rigoutsos, I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455, 1124-1128 (2008).
18. Guo, H., Ingolia, N. T., Weissman, J. S. & Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010).
19. Salmena, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146, 353-358 (2011).
20. Tay, Y. et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147, 344-357 (2011).
21. Miska, E. A. et al. Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet. 3, e215 (2007).
22. Park, C. Y., Choi, Y. S. & McManus, M. T. Analysis of microRNA knockouts in mice. Hum. Mol. Genet. 19, R169-R175 (2010).
23. Small, E. M., Frost, R. J. & Olson, E. N. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121, 1022-1032 (2010).
24. Leung, A. K. & Sharp, P. A. MicroRNA functions in stress responses. Mol. Cell 40, 205-215 (2010).
25. Stenvang, J., Petri, A., Lindow, M., Obad, S. & Kauppinen, S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 3, 1 (2012).
26. Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009).
27. Miyazaki, Y. et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nature Med. 18, 1136-1141 (2012).
28. Bish, L. T. et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359-1368 (2008).
29. Gao, G. et al. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum. Gene Ther. 19, 927-936 (2008).
30. Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080 (2008). (Pubitemid 351737072)
31. Pasquinelli, A. E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nature Rev. Genet. 13, 271-282 (2012).
32. Krutzfeldt, J. et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 35, 2885-2892 (2007). (Pubitemid 47073627)
33. Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
34. Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84 (1999).
35. van Rooij, E., Purcell, A. L. & Levin, A. A. Developing microRNA therapeutics. Circ. Res. 110, 496-507 (2012).
36. Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98 (2006).
37. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
38. Rayner, K. J. et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478, 404-407 (2011).
39. Obad, S. et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nature Genet. 43, 371-378 (2011).
40. Garchow, B. G. et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol. Med. 3, 605-615 (2011).
41. Patrick, D. M. et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120, 3912-3916 (2010).
42. Sheehan, J. P. & Phan, T. M. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 40, 4980-4989 (2001). (Pubitemid 32332544)
43. Henry, S. P. et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Immunopharmacol. 2, 1657-1666 (2002). (Pubitemid 35284605)
44. Swayze, E. E. et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700 (2007). (Pubitemid 46232083)
45. Elmen, J. et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153-1162 (2008). (Pubitemid 351330933)
46. Geary, R. S., Yu, R. Z. & Levin, A. A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2, 562-573 (2001). (Pubitemid 32401151)
47. Elmen, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008). (Pubitemid 351550859)
48. Montgomery, R. L. et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124, 1537-1547 (2011).
49. Chang, J. et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1, 106-113 (2004).
50. Mukherji, S. et al. MicroRNAs can generate thresholds in target gene expression. Nature Genet. 43, 854-859 (2011).
51. Hendrickson, D. G. et al. Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol. 7, e1000238 (2009).
52. Baek, D. et al. The impact of microRNAs on protein output. Nature 455, 64-71 (2008).
53. Selbach, M. et al. Widespread changes in protein synthesis induced by microRNAs. Nature 455, 58-63 (2008).
54. Wolff, J. A. & Budker, V. The mechanism of naked DNA uptake and expression. Adv. Genet. 54, 3-20 (2005).
55. Callis, T. E. et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119, 2772-2786 (2009).
56. van Rooij, E. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579 (2007). (Pubitemid 46683138)
57. van Rooij, E. et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev. Cell 17, 662-673 (2009).
58. Grueter, C. E. et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149, 671-683 (2012).
59. Taubert, S., Van Gilst, M. R., Hansen, M. & Yamamoto, K. R. A mediator subunit, MDT-15, integrates regulation of fatty acid metabolism by NHR-49-dependent and-independent pathways in C. elegans. Genes Dev. 20, 1137-1149 (2006).
60. Wang, W. et al. Mediator MED23 links insulin signaling to the adipogenesis transcription cascade. Dev. Cell 16, 764-771 (2009).
61. Yang, F. et al. An ARC/mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature 442, 700-704 (2006). (Pubitemid 44215326)
62. Frost, R. J. & Olson, E. N. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc. Natl Acad. Sci. USA 108, 21075-21080 (2011).
63. Trajkovski, M. et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649-653 (2011).
64. Zhu, H. et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 147, 81-94 (2011).
65. Ardite, E. et al. PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J. Cell Biol. 196, 163-175 (2012).
66. Liu, G. et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 207, 1589-1597 (2010).
67. Zarjou, A., Yang, S., Abraham, E., Agarwal, A. & Liu, G. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am. J. Physiol. Renal Physiol. 301, F793-F801 (2011).
68. Zhong, X., Chung, A. C., Chen, H. Y., Meng, X. M. & Lan, H. Y. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. 22, 1668-1681 (2011).
69. Hatley, M. E. et al. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 18, 282-293 (2010).
70. Thum, T. et al. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J. Clin. Invest. 121, 461-462; author reply 462-463 (2011).
71. Care, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nature Med. 13, 613-618 (2007). (Pubitemid 46828487)
72. Liu, N. et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22, 3242-3254 (2008).
73. He, J. F., Luo, Y. M., Wan, X. H. & Jiang, D. Biogenesis of miRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J. Biochem. Mol. Toxicol. 25, 404-408 (2011).
74. Porrello, E. R. et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ. Res. 109, 670-679 (2011).
75. Porrello, E. R. et al. Transient regenerative potential of the neonatal mouse heart. Science 331, 1078-1080 (2011).
76. Fang, Y. & Davies, P. F. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler. Thromb. Vasc. Biol. 32, 979-987 (2012).
77. Wu, W. et al. Flow-dependent regulation of Kruppel-like factor 2 is mediated by microRNA-92a. Circulation 124, 633-641 (2011).
78. Parmar, K. M. et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J. Clin. Invest. 116, 49-58 (2006). (Pubitemid 43121790)
79. Kriegel, A. J., Liu, Y., Fang, Y., Ding, X. & Liang, M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol. Genom. 44, 237-244 (2012).
80. Qin, W. et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22, 1462-1474 (2011).
81. Wang, B. et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol. 23, 252-265 (2012).
82. Xiao, J. et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol. Ther. 20, 1251-1260 (2012).
83. Roderburg, C. et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53, 209-218 (2011).
84. Sekiya, Y., Ogawa, T., Yoshizato, K., Ikeda, K. & Kawada, N. Suppression of hepatic stellate cell activation by microRNA-29b. Biochem. Biophys. Res. Commun. 412, 74-79 (2011).
85. Zhang, Y. et al. Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J. Biol. Chem. 287, 14851-14862 (2012).
86. Cushing, L. et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45, 287-294 (2011).
87. Maurer, B. et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62, 1733-1743 (2010).
88. Maegdefessel, L. et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J. Clin. Invest. 122, 497-506 (2012).
89. Merk, D. R. et al. miR-29b participates in early aneurysm development in Marfan syndrome. Circ. Res. 110, 312-324 (2012).
90. Zhang, P. et al. Inhibition of microRNA-29 enhances elastin levels in cells haploinsufficient for elastin and in bioengineered vessels-brief report. Arterioscler. Thromb. Vasc. Biol. 32, 756-759 (2012).
91. Turner, M. & Vigorito, E. Regulation of B-and T-cell differentiation by a single microRNA. Biochem. Soc. Trans. 36, 531-533 (2008). (Pubitemid 351839372)
92. Faraoni, I., Antonetti, F. R., Cardone, J. & Bonmassar, E. miR-155 gene: a typical multifunctional microRNA. Biochim. Biophys. Acta 1792, 497-505 (2009).
93. Tili, E., Croce, C. M. & Michaille, J. J. miR-155: on the crosstalk between inflammation and cancer. Int. Rev. Immunol. 28, 264-284 (2009).
94. Martin, M. M. et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. J. Biol. Chem. 282, 24262-24269 (2007). (Pubitemid 47328062)
95. Sethupathy, P. et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3(f) untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am. J. Hum. Genet. 81, 405-413 (2007). (Pubitemid 47236088)
96. Thai, T. H. et al. Regulation of the germinal center response by microRNA-155. Science 316, 604-608 (2007).
97. Corsten, M. F. et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ. Res. 111, 415-425 (2012).
98. Bang, C., Fiedler, J. & Thum, T. Cardiovascular importance of the microRNA-23/27/24 family. Microcirculation 19, 208-214 (2012).
99. Zhou, Q. et al. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc. Natl Acad. Sci. USA 108, 8287-8292 (2011).
100. Fiedler, J. et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720-730 (2011).
101. Qian, L. et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J. Exp. Med. 208, 549-560 (2011).
102. Boettger, T. et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the mir143/145 gene cluster. J. Clin. Invest. 119, 2634-2647 (2009).
103. Elia, L. et al. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 16, 1590-1598 (2009).
104. Marquart, T. J., Allen, R. M., Ory, D. S. & Baldan, A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl Acad. Sci. USA 107, 12228-12232 (2010).
105. Najafi-Shoushtari, S. H. et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328, 1566-1569 (2010).
106. da Costa Martins, P. A. et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nature Cell Biol. 12, 1220-1227 (2010).
107. Ren, X. P. et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119, 2357-2366 (2009).